Profil
Wendy Dwyer held several business development positions in the pharmaceutical industry, including Director of Business Development at AstraZeneca LP, Vice President of Business Development at Endo Pharmaceuticals, and Vice President of Business Development at Ipsen Bioscience.
She also served as Chief Business Officer at Portal Instruments, Inc. and Saniona AB.
Additionally, she worked as Chief Business Officer at Surface Oncology, Inc. Ms. Dwyer received an undergraduate degree from Endicott College and a graduate degree from Lesley University.
Anciens postes connus de Wendy Dwyer
| Sociétés | Poste | Fin |
|---|---|---|
| SANA AB | Corporate Officer/Principal | 01/01/2022 |
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 26/04/2021 |
Portal Instruments, Inc.
 Portal Instruments, Inc. Medical SpecialtiesHealth Technology Portal Instruments, Inc. operates as a medical device company that focuses on drug delivery systems. It manufactures jet injectors that deliver drugs through the skin without a needle at specific depths and volumes. The firm engages in developing and commercializing a needle-free platform technology to transform the delivery of medicines and improve the patient experience. The company was founded by Patrick A. Anquetil and Ian W. Hunter in 2012 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/03/2019 |
Ipsen Bioscience, Inc.
 Ipsen Bioscience, Inc. BiotechnologyHealth Technology Part of Ipsen SA, Ipsen Bioscience, Inc. is a company that develops and wholesales drugs. The company is based in Cambridge, MA. | Corporate Officer/Principal | 01/01/2017 |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Corporate Officer/Principal | 01/07/2014 |
Formation de Wendy Dwyer
| Endicott College | Undergraduate Degree |
| Lesley University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SANA AB | Health Technology |
| Entreprise privées | 5 |
|---|---|
Portal Instruments, Inc.
Portal Instruments, Inc. Medical SpecialtiesHealth Technology Portal Instruments, Inc. operates as a medical device company that focuses on drug delivery systems. It manufactures jet injectors that deliver drugs through the skin without a needle at specific depths and volumes. The firm engages in developing and commercializing a needle-free platform technology to transform the delivery of medicines and improve the patient experience. The company was founded by Patrick A. Anquetil and Ian W. Hunter in 2012 and is headquartered in Cambridge, MA. | Health Technology |
Endo Pharmaceuticals, Inc.
 Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | Health Technology |
AstraZeneca LP
AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Health Technology |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Ipsen Bioscience, Inc.
Ipsen Bioscience, Inc. BiotechnologyHealth Technology Part of Ipsen SA, Ipsen Bioscience, Inc. is a company that develops and wholesales drugs. The company is based in Cambridge, MA. | Health Technology |